Nasal NK/T cell is a rare form of usually localized non-Hodgkin's lymphoma (NHL) which generally carries a poor prognosis when treated with conventional NHL chemotherapy protocols. We reviewed 20 consecutive localized stage I/II nasal NK/T cell lymphomas treated at our institution over a 29 year period. Median age was 44 (range 23-71). Front-line therapy was generally radiotherapy alone (35-70 Gy) before 1980 and combination chemotherapy after 1980. Six patients were treated with first-line radiotherapy and they achieved complete remission (CR). Two subsequently received combination chemotherapy. Five of those patients remained in complete remission, after 97؉ to 277؉ months. Twelve patients were treated with first-line chemotherapy including CHOP or CHOPlike regimen in seven cases, and COP in five cases. Only three of them achieved CR, five had partial response and four had progressive disease. Five of the seven patients treated with CHOP did not achieve complete remission. The nine patients who failed to achieve CR with chemotherapy subsequently received salvage radiotherapy but only two of them obtained CR. Finally, two patients were treated with alternated chemotherapy and radiotherapy and achieved CR, which persisted after 14+ and 26+ months. Median survival was not reached in patients who received front-line radiotherapy, and was 35 months in patients who received front-line chemotherapy. These findings confirm that chemotherapy gives a low complete remission rate in localized nasal NK/T cell lymphoma. By contrast, first-line radiotherapy seems to give favorable results, whereas its results are poorer when administered after resistance to chemotherapy. Whether the use of chemotherapy after radiotherapy, or alternated chemotherapy-radiotherapy regimens give better clinical results than radiotherapy alone will have to be evaluated prospectively in this type of NHL. Leukemia (2001Leukemia ( ) 15, 1123Leukemia ( -1126 
Introduction
Nasal lymphoma of NK/T cell origin, initially referred to as midline granuloma, clinically presents as a destructive lesion of the midline facial structures. In most cases, it is localized to the nasal cavity, but other median structures of the upper aerodigestive tract can be involved (nasopharynx, oropharynx, palate and larynx). [1] [2] [3] Although this clinical entity is essentially reported in Eastern countries, nasal lymphoma of NK/T cells has also been observed in Western populations. 2, [4] [5] [6] The lymphoid nature of the tumor cells is now well documented. They usually express cytoplasmic CD3, membrane CD56 and are CD3, CD5, and CD16 negative. The T cell receptor gene is usually not rearranged and most of the cases are associated with EBV infection. [4] [5] [6] Correspondence: V Ribrag, Département de Médecine, Institut Gustave-Roussy, Rue C Desmoulins, 94805 Villejuif, France; Fax: 33 1 42 11 52 71 *PF and JB contributed equally as last authors to this work Received 5 June 2000; accepted 13 March 2001 Despite their localized presentation in most patients, nasal NK/T cell lymphomas generally have a poor prognosis when treated with anthracycline-based chemotherapy alone. [4] [5] [6] [7] On the other hand, a favorable role of radiotherapy in the treatment of those lymphomas has been suggested. 2, [8] [9] [10] In most previously published studies, however, all nasal lymphomas were included irrespective of their phenotype (when available), and NK/T cell lymphomas were not analyzed separately. 2, [8] [9] [10] In order to further evaluate the role of radiotherapy in localized nasal NK/T cell lymphomas, we performed a retrospective study of patients with nasal NK/T lymphoma treated at our institution over a period of 29 years.
Patients and methods
From January 1970 to December 1998, 24 patients with primary nasal NK/T cell nasal lymphoma were diagnosed at the Institut Gustave-Roussy. Only 20 of these 24 patients were analyzed in this study: two were excluded because they died before receiving therapy (one from infection and one from an allergic shock during a CT scan); one was excluded as he had stage IV disease and one because of unavailable histological material for immunohistochemical study.
Histological material of the remaining 20 patients fixed in AFA (acidic acid formaldehyde alcool) were reviewed by one of us (JB). Routine stainings including hematoxylin-eosinsafran and Giemsa, immunohistochemical study (IHC) using a panel of monoclonal antibodies (CD3c, CD20, CD4, CD8, CD56, TIA-1, CD30, LMP-1) and in situ hybridization using EBERs probes were performed. Histological material was not available for immunohistochemical and in situ hybridization study in one case.
Patients were staged according to the Ann Arbor classification. All patients had complete physical examination: chest X-rays, full blood count, blood biochemistry, bone marrow biopsy, abdomen ultrasound examination and bipedal lymphography before 1984, and whole body CT scan after 1984.
Before 1980, patients with stage I or II disease were treated with radiotherapy alone. After 1980, most patients received chemotherapy followed or not by radiotherapy. The dose of radiotherapy administered as first-line therapy or after chemotherapy was 35 to 70 Gy to the initial involved areas and the cervical regions when cervical lymph nodes were present. Two patients were treated with alternated chemotherapy and radiotherapy. They received two courses of CHOP each followed by radiotherapy at 20 Gy, then by four additional courses of CHOP. Tumor response was assessed using standard criteria and always included surgical examination of local tumor evolution and biopsies of all suspected areas.
Results
Patients' initial characteristics are shown in Table 1 . Nineteen of the 20 patients were of Western origin and one originated from an Eastern country.
Histologically, tumor cell polymorphism with a mixture of small and medium (10 cases) or medium and large-size tumor (10 cases) irregular lymphoid cells including a common angiocentric, angioinvasive lesions and/or necrotic foci was present. Immunophenotypically, all cases were CD20 − and 18 were TIA-1 + . EBV expression was assessed with LMP1 antibody (16 cases) and/or EBV-encoded small RNAs (EBERs) probes (12 cases) . All the 12 cases tested for both markers of EBV expression had EBER and/or LMP1 positivity. Three of the four cases tested with LMP1 alone were positive. Intracytoplasmic CD3 epsilon chain was present in 16 of the 20 cases tested. Seven of the cases were CD56 + (five CD8 + and two CD8 − ), 12 cases were CD56 − ( Table 2 ) and one case was not assessed for CD56 expression.
The initial presentation site was the nasal cavity (13 patients), palate (three patients) and oropharynx (four patients). Oropharyngeal localization was characterized by multiple chronic ulcerative lesions. Patients always presented with local symptoms (swelling, bleeding, nasal obstruction, painful ulcerations). Fever was present in eight cases, and osteolytic extension was present in 11 cases. Sixteen patients were classified Ann Arbor stage IE, and four stage IIE. No patient had extensive surgery at presentation. Median followup was 97 months for the entire population and 144 months (range 14-300 months) for complete responders.
Six patients received radiotherapy to the tumor area as firstline treatment and they all achieved complete remission. Four of them received no subsequent chemotherapy. Two of the four patients treated with radiotherapy alone remained in CR after 163+ and 144+, and the remaining two relapsed in another oropharyngeal area 133 and 155 months, respectively, after achieving complete remission. They both achieved a second complete remission with radiotherapy alone. One was still in second complete remission of 144+ months' duration, and the other died of a degenerative neurological disease after 300 months of second complete remission, without any sign of relapse. The remaining two initially irradiated patients received eight courses of COP-like chemotherapy and both were alive in complete remission, 97+ and 112+ months after treatment. Two patients received alternated radiotherapy and chemotherapy according to the schedule described above and they achieved complete remission. Both were in complete remission 14+ and 26+ months after treatment.
Twelve patients received first-line chemotherapy, with six to eight courses of CHOP or a CHOP-like regimen (where VP16 was substituted for vincristin) in seven patients, and with eight courses of COP regimen in the five patients treated before 1988. Three of them achieved complete remission, five achieved partial remission and four had progressive disease. Five of the seven patients treated with CHOP did not achieve complete remission. The three complete remitters did not receive subsequent radiotherapy and two of them were alive in complete remission, 53 and 180 months after treatment; the third patient relapsed after 26 months and died of disease progression.
The nine patients who did not achieve complete remission with chemotherapy received salvage radiotherapy. Only two of them achieved complete remission with radiotherapy, of 3 and 4 years duration, respectively, whereas the other patients did not respond and died of their lymphoma. One of these two patients died of unrelated disease (patient No. 19, Table 2 ).
Ten (50%) patients were alive in complete remission, including seven of the eight patients who received radiotherapy early in their treatment regimen (three of those seven patients were treated with radiotherapy alone). Ten patients died, including eight of the 12 patients treated with first-line chemotherapy who died of their disease, and two patients who died of unrelated disease. Disease progression was systemic in two cases, local in three cases and both systemic and local in three cases. None of the four patients treated with radiotherapy alone died from their disease. Only three of the 12 patients treated with first-line chemotherapy were alive in first complete remission, two of them after chemotherapy alone and one after achieving complete remission with salvage radiotherapy. No clinical differences (including age and disease stage) were found between patients treated with early radiotherapy (6/8 were stage I) and those treated with initial chemotherapy alone (10/12 were stage I). Median actuarial survival was not reached in patients who had early radiotherapy, and was 35 months in patients who received first-line chemotherapy (Figure 1 ).
Discussion
Initial chemotherapy with anthracycline-based regimens is the mainstay in the treatment of aggressive NHL, and its success largely depends on a few initial prognostic factors, combined in an International prognostic index (IPI).
11 Despite 'favorable' prognostic factors in most cases (stage I/II lymphoma, good performance status and age of less than 60 years), the outcome of patients with nasal NK/T cell lymphoma treated with first-line chemotherapy was poor in this present study. Only three of the 12 patients treated with first-line chemotherapy achieved complete remission, of which only two were durable. These results on a retrospective study including only 20 patients are in agreement with four previous reports of NK/T cell lymphomas treated with chemotherapy alone including anthracyclines, where only 0/4, 2/16, 5/27 and 6/27, respectively, of the patients with localized nasal NK/T lymphomas achieved durable complete remission. [4] [5] [6] [7] By contrast, all the patients treated with first-line radio- therapy achieved durable complete remission (two of them had a very late relapse). In the only published Western experience to our knowledge of NK/T cells lymphomas treated with first-line radiotherapy, three of the three patients achieved complete remission but follow-up was short (9, 24 and 26 months duration). 2 Three large studies that included Eastern country patients also showed that radiotherapy alone was able to give durable complete remission in more than 50% of localized nasal lymphomas. [8] [9] [10] However, in those studies, patients were included only on a clinical basis (nasal Leukemia presentation) and only about one fourth of the cases were phenotypically documented (most of them had a T cell phenotype). [8] [9] [10] Our results also suggest that radiotherapy gives limited results when given as salvage treatment in patients who do not achieve CR with chemotherapy.
Reasons for primary resistance to chemotherapy in nasal NK/T cell lymphomas, especially by comparison with most other aggressive NHL, are unknown. They could include the usual presence of large necrotic tumoral areas in nasal NK/T lymphomas, leading to poor diffusion of anticancer agents. In three well analyzed cases, it has also been shown that NK/T cell lymphoma cells expressed high levels of P glycoprotein (MDR1). 12 Our study therefore strongly suggests that radiotherapy should be introduced early in the treatment of patients with localized nasal NK/T cell lymphoma. The number of patients where radiotherapy was followed by chemotherapy was too small to assess the role of this adjuvant chemotherapy in preventing systemic relapses. However, in the three studies where radiotherapy was given alone, many of the relapses occurred in non-irradiated areas, suggesting a beneficial role for systemic chemotherapy after local radiotherapy. [8] [9] [10] Alternated radiotherapy and chemotherapy, administered in two patients in the present study, gave good results and should be further explored.
